ANALYSIS OF CLINICAL-PHARMACOLOGICAL APPROACHES TO THE RATIONAL USE OF DRUGS IN CHRONIC HEART FAILURE
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
Abstract:
Chronic heart failure (CHF) is a complex clinical syndrome with high morbidity and mortality. Rational pharmaceutical management is fundamental in improving symptoms, enhancing quality of life, and reducing hospitalizations and mortality. This article reviews current clinical-pharmacological strategies for CHF treatment, emphasizing evidence-based drug classes, therapeutic mechanisms, and rational prescription practices. Key drug categories include angiotensin-converting enzyme inhibitors (ACEIs), beta-adrenergic blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and diuretics. Additionally, new agents and optimization strategies are discussed. Flowcharts and diagrams illustrate treatment pathways and decision points. The analysis supports a patient-centered, risk-benefit approach to drug selection based on comorbidities, renal function, and individual tolerability.
Article Details
How to Cite:
References:
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. European Heart Journal. 2012;33(14):1787–1847.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128:e240–e327.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal. 2016;37(27):2129–2200.
Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC/AHA/HFSA Focused Update on Heart Failure Management. Journal of the American College of Cardiology. 2017;70(6):776–803.
Packer M, McMurray JJ, Desai AS, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014;371:993–1004.
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364:11–21.
Hauptman PJ, Kelly RA. Heart Failure: Pharmacologic Therapies. In: Harrison’s Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2018.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal. 2021;42(36):3599–3726.
Anker SD, Butler J, Bakris GL, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385:1451–1461.
Flather MD, Yusuf S, Køber L, et al. Long-Term ACE Inhibitor Therapy in Patients with Heart Failure or Left Ventricular Dysfunction: A Systematic Overview of Data from Individual Patients. Lancet. 2000;355(9215):1575–1581.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomized Trial. Lancet. 1999;353:9–13.
Gheorghiade M, Bonow RO. Chronic Heart Failure in the United States: A Manifestation of Coronary Artery Disease. Circulation. 1998;97(3):282–289.
Vidović D, Škrabić V, Vrdoljak D. Rational Drug Use in Heart Failure: What Every Clinician Should Know. Journal of Cardiological Pharmacology and Therapeutics. 2019;24(3):202–211.
Farmakis D, Parissis J, Lekakis J, et al. Pathophysiology and Pharmacological Treatment of Acute Heart Failure. Cardiovascular Drugs and Therapy. 2010;24(4):315–327.
Gheorghiade M, Sopko G, De Luca L, et al. Navigating the Crossroads of Heart Failure Care. European Journal of Heart Failure. 2013;15(7):679–680.